Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Midodrine hydrochloride as a treatment for postural orthostatic tachycardia syndrome: A systematic review and meta-analysis.

Journal of cardiovascular pharmacology·2026
Same author

Investigating the impact of problematic evidence on clinical practice guidelines and associated patient outcomes (VITALITY Study II): protocol.

BMJ open·2026
Same author

Hospitalizations During the 30-Day Period Preceding an Admission with Aortic Dissection.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Ivabradine as a Treatment for Postural Orthostatic Tachycardia Syndrome: A Systematic Review.

Journal of cardiovascular pharmacology·2025
Same author

Hospitalisations during the 30-day period preceding admissions with cardiac arrest.

Acta cardiologica·2025
Same author

The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials.

Trends in cardiovascular medicine·2025
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Videos

Adverse drug reactions.

Yoon K Loke1

  • 1Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK. y.loke@uea.ac.uk

British Journal of Clinical Pharmacology
|February 25, 2012
PubMed
Summary
This summary is machine-generated.

Understanding adverse drug reactions requires a shift towards biological mechanisms and patient factors. Enhanced drug safety research, through collaboration and rapid-response networks, is crucial for effective patient and physician management at the bedside.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Pharmacoepidemiology
  • Drug Safety Research

Background:

  • Current understanding of adverse drug reactions (ADRs) is limited by insufficient focus on biological mechanisms, patient susceptibility, and long-term consequences.
  • Existing drug safety assessments often prioritize industry and regulatory viewpoints over clinical application.

Purpose of the Study:

  • To advocate for an evidence-based approach to ADR prevention and management.
  • To emphasize the need for enhanced collaboration between clinical pharmacologists and pharmacoepidemiologists.
  • To propose the establishment of a rapid-response research network for comprehensive drug safety analysis.

Main Methods:

  • Interrogation of electronic healthcare databases.
  • Application of teleoanalysis techniques for risk assessment.
  • Collaborative research between clinical pharmacology and pharmacoepidemiology.

Main Results:

  • Identified limitations in current ADR understanding and assessment.
  • Highlighted the potential of advanced data analysis for drug safety.
  • Proposed a model for improved drug safety research infrastructure.

Conclusions:

  • A shift towards mechanistic and patient-centered research is essential for improving ADR management.
  • Collaboration and independent, rapid-response research networks are vital for addressing emerging drug safety concerns.
  • Clinicians and patients need better tools and information for bedside ADR management.